Heron Therapeutics, Inc.
Profile
Our portfolio includes two products approved by the US Food and Drug Administration, SUSTOL® (granisetron) and CINVANTI (aprepitant) injectable emulsion, as well as one product in development; HTX-011, a fixed-dose combination of the local anesthetic bupivacaine with the nonsteroidal anti-inflammatory drug (NSAID) meloxicam being investigated for application into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours.
Heron’s mission is to improve patient’s lives by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to proven pharmacological agents.